Aims: We sought to assess the risk of major adverse cardiovascular events (MACE) by utilizing high-sensitivity C-reactive protein (hsCRP) level and low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes and recent acute coronary syndrome.
those according to systolic blood pressure, total cholesterol and nonhigh-density lipoprotein (HDL) cholesterol levels. 4 In a meta-analysis addressing secondary prevention, hsCRP concentrations measured within 72 hours from the onset of acute coronary syndrome (ACS)
were associated with a higher long-term risk of recurrent CV events. 5 However, because hsCRP rises 5 to 8 times in the setting of ACS, the cut-points used in the acute setting differ from those used in a stable population.
To date, several prospective studies have examined the role of hsCRP in predicting future CV morbidity and mortality in stable patients with type 2 diabetes mellitus, with varying results. [6] [7] [8] [9] [10] [11] [12] The aim of our study was to determine whether the baseline hsCRP level is predictive of the risk of major adverse cardiovascular events (MACE), a composite of cardiovascular death, non-fatal myocardial infarction and stroke, in patients at high risk of CV disease, with type 2 diabetes and recent ACS, who were enrolled in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial. 13 In addition, we evaluated whether the associations between hsCRP level and future CV outcomes were independent of achieved low-density lipoprotein (LDL) cholesterol (LDL-C) levels.
| METHODS

| Study design and patients
The design of the EXAMINE study has been published previously. 13 EXAMINE was a multicenter, randomized, double-blind study that evaluated the efficacy and safety of the dipeptidyl peptidase 4 (DPP-4) inhibitor alogliptin in 5380 patients diagnosed with type 2 diabetes and ACS within 15 to 90 days before randomization. Other inclusion criteria required a glycated haemoglobin level of 6.5% to 11.0% at baseline or, if the antidiabetic regimen included insulin, a glycated haemoglobin level of 7.0% to 10.0%. Major exclusion criteria were diagnosis of type 1 diabetes; unstable cardiac disorders including New York Heart Association Functional Classification IV heart failure, refractory angina, uncontrolled arrhythmia, critical valvular heart disease or severe uncontrolled hypertension; and dialysis within 14 days before screening.
Patients were randomly assigned to receive alogliptin or placebo, administered in a double-blind fashion, in addition to standard-ofcare treatment for type 2 diabetes. Throughout the study, patients were required to receive standard-of-care treatment for type 2 diabetes and CV risk factors according to regional guidelines. Because alogliptin is cleared by the kidney, alogliptin and matching placebo doses were modified according to the estimated glomerular filtration rate (GFR, MDRD) at baseline and after randomization.
| Cardiovascular adjudication
The composite MACE endpoint consisted of cardiovascular death, non-fatal acute myocardial infarction and non-fatal stroke. Cardiovascular death was defined as death from cardiac and cerebrovascular causes and any death without another known cause. Urgent revascularization because of unstable angina, hospitalization for heart failure, and death as a result of any cause were adjudicated also. CV events and all deaths were adjudicated by members of an independent cardiovascular endpoints committee who were blinded to treatment assignment (Cleveland Clinic Cardiovascular Endpoint Committee, Cleveland, Ohio).
| Measurement of hsCRP
Venous blood samples were obtained in EDTA-treated tubes at study entry as part of the study protocol. Plasma samples were refrigerated and transported overnight to the central laboratory, and were stored at −80 C or colder until analysed after a single freeze-thaw cycle.
The hsCRP was measured at baseline in all available samples (n = 5380) using a validated latex-enhanced turbidimetric immunoassay (Hitachi 747 analyzer). All assays were performed by laboratory personnel blinded to treatment allocation and clinical outcome. 
| Statistical analysis
| RESULTS
The baseline characteristics of study participants according to baseline hsCRP concentrations (<1, 1-3, and >3 mg/L) are shown in Table 1 . Of the 5380 subjects who had an hsCRP concentration measured at baseline, approximately 40% (n = 2139) had an hsCRP concentration of >3 mg/L. Patients with higher hsCRP levels (>3 mg/L) were more obese, and more likely to have higher blood pressure; had higher fasting glucose, glycated haemoglobin, LDL-C and triglyceride levels; and had lower HDL cholesterol levels than patients with average to lower hsCRP levels (≤3 mg/L). The high hsCRP patients were also more likely to be current smokers and have a history of hypertension, coronary bypass surgery, congestive heart failure or peripheral artery disease, and were less likely to have a history of percutaneous coronary intervention.
During a median duration of 18 months of follow-up, cumulative incidences of MACE were 11.5% (119 events), 14.6% (209 events) and 18.4% (287 events) in patients with baseline hsCRP <1, 1 to 3 and >3 mg/L, respectively (P < .001) ( Figure 1 ). Similarly, cumulative incidences of hospitalization for heart failure or death from any cause were related to baseline hsCRP levels (both P < .001). No differences in the rates of urgent revascularization for unstable angina were observed across the hsCRP concentrations ( Figure S1 ).
In patients with baseline hsCRP >3 mg/L, the adjusted hazard ratio (HR) (95% confidence interval [CI]) was 1.42 (95% CI, 1.13,
1.78; P = .002) for MACE, 1.40 (95% CI, 1.04, 1.89; P = .025) for non-fatal myocardial infarction, 2.04 (95% CI, 1.34, 3.11; P < .001)
for hospitalization following heart failure and 1.77 (95% CI, 1.29, 2.42; P < .001) for death from any cause, compared to patients with baseline hsCRP <1 mg/L, and were independent of treatment group, age, sex, body mass index, current smoking status, total cholesterol, estimated GFR, blood pressure, glycated haemoglobin and duration of diabetes. Baseline hsCRP concentrations did not show an independent association with the individual endpoints of death from cardiovascular causes, non-fatal stroke or urgent revascularization because of unstable angina. In addition, patients with average concentrations of hsCRP (1-3 mg/L) had a CV risk comparable to patients with lower baseline hsCRP concentrations (<1 mg/L) ( Table 2) .
Results for the groups evaluated according to both baseline hsCRP (≤3 or >3 mg/L) and achieved LDL-C (<70 or ≥70 mg/dL) levels are shown in Figure 2 . Cumulative incidences of MACE were 11.0% (128 events), 14.4% (100 events), 15.6% (194 events) and 21.3% (182 events) in patients with low LDL-C and low hsCRP concentrations, low LDL-C and high hsCRP concentrations, high LDL-C and low hsCRP concentrations, and high LDL-C and high hsCRP concentrations, respectively (P < .001). Hospitalization for heart failure and death from any cause were also related to both baseline hsCRP and achieved LDL-C levels (both P < .001). Cumulative incidences of urgent revascularization for unstable angina were similar among the 4 groups ( Figure S2 ). It has been suggested that the association between hsCRP level and risk of CV disease is generally weaker in patients with type 2 diabetes compared with those without diabetes. [16] [17] [18] Type 2 diabetes is characterized by diverse CV risk factors including high triglycerides and low HDL cholesterol levels, hypertension and hyperglycaemia per se, and these multiple risk factors may partially mask the role of hsCRP as a risk factor for CV morbidity and mortality. [16] [17] [18] In an Moreover, the efficacy of statins was not different according to achieved CRP levels, and thus, the authors did not support the use of CRP as an indicator of statin efficacy in patients with type 2 diabetes. 10 Collectively, these data suggested that, in populations with increased inflammatory and vascular burden, the measurement of hsCRP may have limited clinical relevance in the assessment of future development of CV events.
In contrast, several prospective cohort studies have shown that individuals with higher CRP levels were at risk of future CV disease, including patients with type 2 diabetes. [6] [7] [8] [9] In a population-based Italian cohort, followed for 5 years, higher CRP values (>3 mg/L) were associated with increased overall and CV mortality in patients with type 2 diabetes after adjusting for conventional CV risk factors. 6 Similarly, in a study involving 878 Finnish subjects with type 2 diabetes who were free of myocardial infarction at baseline, coronary heart disease mortality was increased in subjects with a higher CRP level (>3 mg/L). 7 Therefore, there is still equipoise regarding the usefulness of measuring the hsCRP level to assess CV risk in patients with a high vascular risk, including those with type 2 diabetes and previous CV disease from the ADVANCE study 11 and those with ACS.
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While there is a discrepancy between some of the above- Another key finding of our analysis is that the hsCRP value was independent of, and additive to, the achieved LDL-C level in predict- reduction, but also hsCRP reduction, could be induced by statin therapy. 21 Finally, the PROVE IT-TIMI 22 trial demonstrated that hsCRP reduction is beneficial in preventing vascular events, whether or not LDL-C levels were reduced to the target value of <70 mg/dL with statin treatment. 22 In EXAMINE, the cumulative incidences of MACE, hospitalization for heart failure and death from any cause were the lowest in 
